Abstract
Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, breaks down abstract summaries published in The ASCO Post on a novel target, imaging agent, and androgen-deprivation therapy for prostate cancer, along with their implications for advanced practitioners.
